Markets:

Overview

News

Currencies

International

Treasuries

Enveric Biosciences, Inc. - Common Stock (NQ:ENVB)

2.296 -0.054 (-2.31%)

Streaming Delayed Price Updated: 2:00 PM EST, Mar 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Enveric Biosciences, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

16 17 Next >

Why Is Anxiety/Addiction-Focused Enveric Biosciences Stock Trading Higher Tuesday? ↗

March 19, 2024

Enveric Biosciences announces significant progress with non-binding term sheets signed with a biotech firm for cannabinoid-COX-2 conjugate compounds, targeting joint diseases. These agreements could...

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗

March 19, 2024

Via Benzinga

Enveric Biosciences Signs Non-Binding Term Sheets to Pursue the Exclusive Out-Licensing of New Chemical Entities for Pharmaceutical and Non-Pharmaceutical Applications in Joint Disease

March 19, 2024

From Enveric Biosciences

Via Business Wire

Psychedelics Headlines: Substitution Survey, Frank Herbert's Magic Mushrooms, Celestial Plans And News Review ↗

March 16, 2024

Via Benzinga

Why Is Enveric Biosciences (ENVB) Stock Up 120% Today? ↗

February 29, 2024

Investors in Enveric Biosciences are seeing massive gains today, as ENVB stock more than doubles on a huge uptick in trading volume.

Via InvestorPlace

Enveric Biosciences Announces New Patent Issuances Protecting Multiple Assets Covered by Non-Binding Term Sheets

March 12, 2024

From Enveric Biosciences

Via Business Wire

Psyched: New Evidence Shows Psilocybin As Anxiety Therapy, Open-Source Learning For Therapists, Enveric's Licensing Deals And More ↗

March 04, 2024

Via Benzinga

S&P 500 Moves Higher; Hayward Holdings Shares Jump On Upbeat Results ↗

February 29, 2024

U.S. stocks traded mixed toward the end of trading, with the S&P 500 gaining around 0.3% on Thursday. The Dow traded down 0.08% to 38,919.26 while the NASDAQ rose 0.53% to 16,032.35. The S&P 500 also...

Via Benzinga

Topics Stocks

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

February 29, 2024

Via Benzinga

Why Butterfly Network Shares Are Trading Lower By 22%? Here Are Other Stocks Moving In Thursday's Mid-Day Session ↗

February 29, 2024

Shares of Butterfly Network, Inc. (NASDAQ: BFLY) fell sharply during Thursday’s session after the company reported mixed fourth-quarter financial results.

Via Benzinga

Crude Oil Moves Higher; Best Buy Posts Upbeat Earnings ↗

February 29, 2024

U.S. stocks traded mixed midway through trading, with the Nasdaq Composite gaining around 100 points on Thursday. The Dow traded down 0.16% to 38,884.96 while the NASDAQ rose 0.38% to 16,008.19. The...

Via Benzinga

Topics Stocks

Why Enveric Biosciences Stock Is Soaring ↗

February 29, 2024

Enveric said it could be eligible to receive future development and sales milestone payments and execution fees for the three licenses, which in total could add up to $200 million, assuming certain...

Via Benzinga

Nasdaq Gains 100 Points Following PCE Data ↗

February 29, 2024

U.S. stocks traded mostly higher this morning, with the Nasdaq Composite gaining around 100 points on Thursday. Following the market opening Thursday, the Dow traded down 0.07% to 38,923.11 while the...

Via Benzinga

Topics Stocks

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

February 29, 2024

Via Benzinga

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday ↗

February 29, 2024

It's time to dive into the biggest pre-market stock movers for Thursday as we check out all of the news affecting shares this morning!

Via InvestorPlace

Enveric Biosciences Signs Non-Binding Term Sheets to Pursue the Exclusive Out-Licensing of Three Classes of Compounds

February 29, 2024

From Enveric Biosciences

Via Business Wire

EXCLUSIVE: Enveric Biosciences Announces Non-Binding Deals To License Out Three Types of Drug Compounds ↗

February 29, 2024

Via Benzinga

Medical Breakthrough Stocks Under $1: OCGN, VERO, RSCI, VTAK, ENVB

February 28, 2024

Via AB Newswire

Topics Intellectual Property

Enveric Biosciences Sells Cancer Patents As It Paves Way For Mental Health Treatments ↗

February 23, 2024

Enveric Biosciences Inc. has announced the sale of a cancer-related patent portfolio, including patents and pending applications in several countries, focusing on cannabidiol as a treatment for cancer....

Via Benzinga

Topics Intellectual Property

12 Health Care Stocks Moving In Friday's Intraday Session ↗

February 23, 2024

Via Benzinga

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

February 23, 2024

Via Benzinga

Enveric Biosciences Agrees to Sell Cancer-Targeting Cannabinoid-Related Intellectual Property

February 23, 2024

From Enveric Biosciences

Via Business Wire

Enveric Biosciences Deepens Its Mental Health-Focused Pipeline With Library of Preclinical Compounds ↗

February 21, 2024

Enveric Biosciences announced discovery of multiple compounds using its Psybrary platform and AI system. These compounds broaden their range of mental health treatments.

Via Benzinga

Topics Artificial Intelligence

Enveric Biosciences Unveils Library of Preclinical Compounds Across Multiple Distinct Molecule Classes Targeting Mental Health Disorders

February 21, 2024

From Enveric Biosciences

Via Business Wire

Psyched: Psychedelics & Sex, MDMA And Federal Approval, Canadians For End-Of-Life Care And More ↗

February 15, 2024

Via Benzinga

Psyched: Suggestibility And Psychedelics' Effects, EU's $7M Research Fund, Australia's Treatment Delivery, BZ Podcast And More ↗

January 27, 2024

New study finds suggestibility plays a role in antidepressant effects of psilocybin therapy. EU invests 6.5M euros in psychedelics for pulmonary disorder, MS, ALS, and Parkinson's. Australian...

Via Benzinga

Psyched: $100M For MDMA Therapy, VA Funds, 2024 Watchlist, Reform Updates And More ↗

January 12, 2024

Psychedelics Developer Secures $100M In Series A Funding, Will Support MDMA Approval To Treat PTSD

Via Benzinga

30 Psychedelics Executives, Scientists & Influencers To Watch In 2024 And Beyond ↗

January 10, 2024

The emerging psychedelics industry is expanding rapidly across the globe. With research demonstrating promising therapeutic potential for substances like psilocybin and MDMA to treat mental health...

Via Benzinga

Psyched: Ibogaine For TBI, Kentucky Initiative Stalled, DEA Quotas, Insurance Codes, Atai's $50M And More ↗

January 07, 2024

Ibogaine Therapy Shows Promising Outcomes For Veterans With Trauma Brain Injury

Via Benzinga

Enveric Biosciences Updates Key Data Underpinning Selection of EB-003 as Lead Drug Candidate from EVM301 Series

January 03, 2024

From Enveric Biosciences

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9

...

16 17 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.